BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

Other equities analysts also recently issued reports about the company. JPMorgan Chase & Co. initiated coverage on BridgeBio Oncology Therapeutics in a report on Wednesday, July 8th. They set an “overweight” rating and a $27.00 price target for the company. UBS Group cut shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $23.00 price objective on the stock. Finally, Oppenheimer began coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.80.

BridgeBio Oncology Therapeutics Price Performance

BridgeBio Oncology Therapeutics stock opened at $8.42 on Friday. The stock has a market cap of $674.53 million, a P/E ratio of -4.11 and a beta of 0.39. The stock has a 50 day moving average of $8.17. BridgeBio Oncology Therapeutics has a twelve month low of $7.00 and a twelve month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. Research analysts predict that BridgeBio Oncology Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP lifted its stake in BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after acquiring an additional 395,608 shares during the period. Laurion Capital Management LP grew its stake in shares of BridgeBio Oncology Therapeutics by 40.1% in the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after acquiring an additional 419,138 shares during the period. Armistice Capital LLC raised its holdings in shares of BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after purchasing an additional 588,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of BridgeBio Oncology Therapeutics by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after purchasing an additional 20,385 shares during the last quarter. Finally, Catalio Capital Management LP bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $5,142,000. 54.89% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.